Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07845513). This is a study registration, not published results. Lead sponsor: Pfizer. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 16 participants (ESTIMATED). Conditions: Overweight, Obesity, Healthy Adults. Interventions: DRUG: PF-08653944. Primary outcome measures: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of PF-08653944 , Up to 85 days; PK: Maximum Observed Concentration (Cmax) of PF-08653944 , Up to 85 days. Brief summary: The purpose of this study is to learn about: * How PF-08653944 is changed and removed from the body after taken * Safety of PF-08653944 * The extent to which side effects can be tolerated after taking PF- 08653944 for the possible treatment of heart failure This study is seeking participants who: * Are healthy Chinese adults who are aged 18 years and older * Have body mass index of 24 - 45 kilograms/meter2 * Have a total body weight of equal to or more than 50 kilograms (110 pounds) * Do not have prior significant medical conditions, history of drug or alcohol abuse All participants in this study will receive a single dose of PF-08653944 at the study clinic. The experiences of the participants receiving the study medicine will be looked at. This will help to see if the study medicine is safe. Participants will take part in this study for around 16 weeks. During this time, they will have 6 study visits at the study clinic.